Thu Sep 26 12:59:59 UTC 2024: ## Institutional Investors Show Interest in Supernus Pharmaceuticals
**Baltimore, MD – September 26, 2024** – Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing treatments for central nervous system disorders, has seen an uptick in interest from institutional investors. XTX Topco Ltd, a prominent investor, recently purchased a new position in the company during the second quarter, acquiring 15,670 shares valued at approximately $419,000.
This move follows other recent investments by institutional investors, including Fidelis Capital Partners LLC, EntryPoint Capital LLC, Meeder Asset Management Inc., Innealta Capital LLC, and nVerses Capital LLC, all of whom acquired new positions in Supernus Pharmaceuticals during the first and second quarters.
Supernus Pharmaceuticals’ stock opened at $29.94 on Thursday, with a market capitalization of $1.65 billion. The company’s stock has experienced a range of $21.99 to $35.44 over the past year.
Analysts’ opinions on the company remain mixed. Piper Sandler downgraded Supernus Pharmaceuticals from “overweight” to “neutral” and reduced its target price to $36.00 from $41.00, while StockNews.com upgraded the stock from “buy” to “strong-buy.”
Supernus Pharmaceuticals currently markets Trokendi XR and Oxtellar XR, medications for epilepsy and migraine headaches. The company is continuing to develop new treatments for CNS diseases.
For further insights into Supernus Pharmaceuticals and its investor activity, visit HoldingsChannel.com for the latest 13F filings and insider trades.
First Piper 